Replies to post #423234 on Anavex Life Sciences Corp (AVXL)

[bas2020]

Missling has likely read the very astute posts of biocheckers who criticized him for spreading himself and the company too thin with all these ancillary indications, and has decided to focus on Rett and AD for the time being.

[crescentmotor]

He has missed a lot with no explanations ever.

That's one of the few things I don't like about Missling. He seems to launch hopes of new trials on a very premature basis--in fact sometimes years before he can actually start the trials. That translates into lack of transparency and unnecessary disappointment.

[mike_dotcom]

<<the new rare disease that we don’t know what it is yet is about eight months late>> More like two years. They will NEVER reveal what that is. They are hoping people just forget. Maybe they're hoping that all their investors get Alzheimers.

[Gator328]

Dr. Missling has a finite amount of time and money. He's also in an impossible situation because if he spends time getting other trials started it'll slow down Rett and Alzheimer's and he'll be criticized for not getting those across the finish line ASAP.

Dr. Missling's attention appears to be shifting away from the science and more toward business strategy. He's heard shareholder demands for revenue immediately, recognized Rett is the best path forward (and we get a priority review voucher!), but that means a few other trials have to wait a bit longer in the queue.

It's really a first world problem if you think about it. Sigma-1 activation could play a role in so many different brain functions that we don't have the time or money to test them all simultaneously. Some indications will have to wait their turn. No big deal, as long as there's progress being made with Rett and Alzheimer's it's all good.